Cases have been reported of patients with concurrent RA and RHS while on infliximab and tocilizumab, TNF-α, and interleukin 6 (IL-6) inhibitory monoclonal antibodies, respectively [9,10]. The gene discussed is TNF; the disease is leukocyte adhesion deficiency type II.